Check your Patent Term Adjustments (PTA): What you Need to Know about the USPTO Error

by Dennis Crouch

The United States Patent and Trademark Office (USPTO) has disclosed a significant error in its patent term adjustment (PTA) calculations, potentially affecting patents issued between March 19, 2024, and July 30, 2024.

The USPTO discovered a coding error introduced in a recent software update. This error specifically affected two aspects of the PTA calculation:

1. The "A" delay under 35 U.S.C. 154(b)(1)(A)
2. The amount of overlap under 35 U.S.C. 154(b)(2)(A)

Importantly, other components of the PTA calculation were not impacted by this error. The USPTO estimates that approximately 1% of patents issued during the affected period may have been impacted.  In many cases, the overall PTA remained correct because the inaccurate "A" delay equaled the inaccurate "Overlap." However, in some instances, these inaccuracies didn't balance out.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The Historical Roots of Patent Injunctions: Revisiting Horton v. Maltby (1783)

by Dennis Crouch

In the ongoing debate over the proper standard for issuing injunctions in patent cases, a 240-year-old English Chancery decision has taken on renewed significance. Horton v. Maltby, LI Misc MS 112 (Ch. 1783), provides a window into the traditional principles of equity that modern U.S. courts are instructed to apply when considering injunctive relief for patent infringement.

The case arose when Horton, who had obtained a patent for a stocking-making machine, filed a bill in Chancery (England's primary court of equity until 1875) against Maltby for allegedly infringing the patent. Horton sought three equitable remedies: accounting of profits, delivery or destruction of the infringing machines, and an injunction to prevent further use. Maltby requested immediate dismissal via demurrer, arguing that Horton should first establish his right at law before seeking equitable relief.

Lord Ashurst, wrote the primary opinion rejecting the demurrer. His opinion draws a parallel between patent and copyright cases, noting that in both instances, ongoing infringement during litigation could cause "irreparable injury" to the rights holder. The opinion's reasoning suggests that the mere fact of continued infringement during the litigation was sufficient to establish irreparable harm—a key factor in granting injunctive relief.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Free Post: Not Yet in Effect: Clarifying Misconceptions About the USPTO’s Proposed Terminal Disclaimer Rule

by Dennis Crouch

I wanted to provide a quick update on potential misinformation that came out in a panel that I was part of at the IPO annual conference.  One speaker noted that the USPTO terminal disclaimer rules were already in effect. That is not true.  In May 2024, the agency released a notice of proposed rulemaking (NPRM) and has not yet indicated whether it will finalize the rules.  Terminal disclaimers filed today are not bound by the potential rule that appears to be intended to apply only prospectively to new terminal disclaimers filed after the rule goes into effect.  The disclaimer process is a formal written process, and the proposed rule would require new language to be included in terminal disclaimers filed to obviate nonstatutory double patenting. And seemingly, this new required language would only apply to terminal disclaimers filed after the rule becomes effective.

Although the proposed rule is not yet in effect, it may soon be finalized.  And, once finalized would have a dramatic impact on terminal disclaimer and continuation practice in the U.S.  Many of us believe that the rules – in their current form – are unlikely to be enforceable. However there is a key difference between requiring a party to sign a disclaimer, and the impact of such a disclaimer if signed. (more…)

Federal Circuit Grants En Banc Rehearing in EcoFactor v. Google, Limiting Damages Expert Testimony

by Dennis Crouch

The U.S. Court of Appeals for the Federal Circuit has granted Google's en banc rehearing in EcoFactor, Inc. v. Google LLC, No. 2023-1101 (Fed. Cir. Sept. 25, 2024), focusing on the admissibility of expert testimony regarding patent damages. This will be the first en banc utility patent case since 2018.

The order vacates the panel's previous decision that had sided with the patentee and calls for new briefing on: whether the district court properly applied Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in allowing testimony from EcoFactor's damages expert. The court has set a tight briefing schedule, with Google's opening brief due in 45 days, EcoFactor's response due 45 days later, and Google's reply due 30 days after that. Notably, the court is also welcoming amicus briefs without requiring consent or leave.  This is an important case to the patent community.  Under eBay and its progeny, equitable remedies are already tightly limited, and this case is looking to similarly tie-down damages theories to prevent large damage awards and provide further mechanisms to allow a judge to decide the outcome rather than a jury.

I begin this post with pessimism about the fundamental inquiry into patent damages.  In most cases, I see patent damages as inherently speculative. The law's hypothetical negotiation to reach a reasonable royalty is a counter-factual endeavor set so far apart from reality that its results have little real meaning.  In typical infringement cases,  there is no overlap between amounts acceptable to either party.  The baseline for a hypothetical royalty is typically determined by what the court would likely award in damages. However, this creates a circular problem, as the court's award is itself based on the hypothetical royalty. This circularity makes it challenging to establish a truly objective starting point for damage calculations.  Even when we have evidence of prior licenses -- those tend to be in wholly different scenarios where the patents have not yet been adjudged enforceable and infringed.   This distinction is important because every case I have encountered at the licensing stage includes credible arguments from the potential licensee that the patent is either not-enforceable or not-infringed.  Thus, although I see the hypothetical negotiation as a useful tool, our attempts to tightly align the historical fiction with the actual practice of patent licensing simply does not provide a real answer as to the results of such a hypothetical negotiation.

The inherent speculativeness of the hypothetical negotiation relates directly the Daubert standard and Rule 702.  In particular, the law requires that expert testimony on damages be based upon "reliable principles and methods."  And, I would reject any approach that, because of the difficulty in providing this evidence, would place a heightened burden on patentees to show they are deserving of a damage award associated with adjudged infringement.  At the same time, we have to recognize that damages experts are paid large rates because they are compelling witnesses - and there are many examples of experts using their persuasive skills to convincingly present dubious methodologies or unsupported conclusions as scientific fact. The limits imposed by Rule 702 serve a crucial purpose in this context. The gatekeeping function of the court under Daubert is particularly important in patent cases, where the technical complexity of the subject matter and the large sums at stake can make jurors especially susceptible to well-presented but potentially flawed expert opinions.  This is not an emperor's new clothes situation where a child can easily see the nakedness. The intricate patterns of economic theories, market analyses, and technical valuations woven by damages experts can be so sophisticated that even experienced judges and attorneys may find it challenging to identify flaws or inconsistencies.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Disparaging in Context: Motivation to Combine Exists Even For a Markedly Inferior Element

by Dennis Crouch

In a nonprecedential opinion, the Federal Circuit affirmed the PTAB decision finding all claims of Novartis's U.S. Patent No. 9,220,631 unpatentably obvious. Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc., No. 2023-1334 (Fed. Cir. Sept. 23, 2024). The court rejected a teaching-away argument even though the prior art had described a key component as "markedly inferior."


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.